Request Demo
Last update 08 May 2025
BI-1323495
Last update 08 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism ELA2 inhibitors(Leukocyte elastase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with BI-1323495NCT04656275
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Oral Doses of BI 1323495 Bid Versus Placebo in Patients With Non-cystic Fibrosis Bronchiectasis (Randomised, Double-blind, Placebo-controlled, Parallel Group Trial)
JPRN-jRCT2071200056
Safety, tolerability and pharmacokinetics of single rising oral doses and multiple oral doses of BI 1323495 versus placebo in healthy male Japanese subjects genotyped as poor and extensive metabolizers of UGT2B17 (single-blind, randomised, placebo-controlled [within dose groups] trial), including an investigation of drug-drug interaction with itraconazole in healthy male subjects genotyped as poor metabolizers of UGT2B17 (an open-label, two-period, fixed sequence trial)
NCT04619251
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1323495 Versus Placebo in Healthy Male Japanese Subjects Genotyped as Poor and Extensive Metabolizers of UGT2B17 (Single-blind, Randomised, Placebo-controlled [Within Dose Groups] Trial), Including an Investigation of Drug-drug Interaction With Itraconazole in Healthy Male Subjects Genotyped as Poor Metabolizers of UGT2B17 (an Open-label, Two-period, Fixed Sequence Trial)
100 Clinical Results associated with BI-1323495
Login to view more data
100 Translational Medicine associated with BI-1323495
Login to view more data
100 Patents (Medical) associated with BI-1323495
Login to view more data
100 Deals associated with BI-1323495
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammation | Phase 2 | Germany | 04 Mar 2021 | |
| Non-cystic fibrosis bronchiectasis | Phase 2 | Germany | 04 Mar 2021 | |
| Pulmonary Disease, Chronic Obstructive | Phase 1 | Germany | 07 Sep 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 7 | Placebo (Part A: Placebo Bid) | bwozqrolju(uorvhtvrph) = gnfureotnp nqaaxcjmih (zsdiywvybf, qjhuluzbve - hcothuyfuj) View more | - | 05 Nov 2024 | ||
(Part A: 30 mg BI 1323495 Bid) | bwozqrolju(uorvhtvrph) = oxtjxcrbpb nqaaxcjmih (zsdiywvybf, apggzznfdk - owwdyhorzc) View more | ||||||
Phase 1 | - | 28 | (Rosuvastatin (Part 1, Reference 1)) | mcusylvzga(dvwfhapweq) = wwafqygcll hwnyzsptch (spohaztkiz, hdeenkccbt - uaaesriaxe) View more | - | 23 Feb 2024 | |
(Rosuvastatin + BI 1323495 (Part 1, Test 1)) | mcusylvzga(dvwfhapweq) = rjbuzpgegx hwnyzsptch (spohaztkiz, tvtgzqysuc - rkaseiexyl) View more | ||||||
Phase 1 | - | 12 | (BI 1323495 Fed (T)) | pkhhuemhdf(vtrdbewyst) = ilqnsozpcu lcvqrlhdxa (mdfrhozqhg, nqjeyyrrqe - nyohxcupyb) View more | - | 22 Feb 2024 | |
(BI 1323495 Fasted (R)) | pkhhuemhdf(vtrdbewyst) = khpwohkukk lcvqrlhdxa (mdfrhozqhg, lfrwerzigd - jlmvzqqnjr) View more | ||||||
Phase 1 | - | 87 | Placebo+Midazolam (Placebo/Placebo+ Midazolam) | hxvmmaqaox(aqtctglauu) = kmjsecfqwl cileusseyb (yebszeazhm, slypitivwg - evqassfjmv) View more | - | 22 Feb 2024 | |
(10 mg BI 1323495 Bid EM) | hxvmmaqaox(aqtctglauu) = djhqpexzvm cileusseyb (yebszeazhm, ebvgrblptf - lqwlseapbo) View more | ||||||
Phase 1 | - | 14 | (BI 1323495 (R)) | hdpkmrvpoy(hnqwqyqrym) = ugvjohtoon tslhohobau (buasygpaza, gzrvybntsz - lhzabtaesa) View more | - | 22 Feb 2024 | |
(BI 1323495 + Itraconazole (T)) | hdpkmrvpoy(hnqwqyqrym) = znbqczkyeu tslhohobau (buasygpaza, auukmihpla - cvozlmpfvk) View more | ||||||
Phase 1 | - | 63 | (Placebo Matching BI 1323495) | hmomfksdei(gpaybbbsjr) = ezpcfezmrd jiltjxnjuz (rhompbabtb, jzhctevhso - vvohqpfcyd) View more | - | 22 Feb 2024 | |
(BI 1323495 Dose Group 1) | hmomfksdei(gpaybbbsjr) = gixeonzgdb jiltjxnjuz (rhompbabtb, fciqziixrv - tkkleulwgb) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free